<DOC>
	<DOCNO>NCT01799941</DOCNO>
	<brief_summary>The objective study evaluate safety , tolerability , effectiveness NUEDEXTA capsule contain 20 mg DM ( Dextromethorphan ) /10 mg Q ( Quinidine ) treatment Pseudobulbar Affect ( PBA ) patient prevalent condition dementia , stroke , traumatic brain injury ( TBI ) 12 week period .</brief_summary>
	<brief_title>Safety , Tolerability Effectiveness Nuedexta Treatment Pseudobulbar Affect ( PBA )</brief_title>
	<detailed_description>This Open-label , Multicenter , study patient PBA dementia , stroke TBI . Patients clinical diagnosis PBA meet inclusion exclusion criterion eligible participate receive NUEDEXTA 12 week . Males females patient minimum age 18 year , clinical diagnosis Pseudobulbar Affect document diagnosis neurologic disease brain injury , enrol study . The primary effectiveness endpoint mean change Center Neurologic Study-Lability scale ( CNS-LS ) . Secondary objective include measure evaluate treatment outcome .</detailed_description>
	<mesh_term>Brain Injuries</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Dextromethorphan</mesh_term>
	<mesh_term>Quinidine</mesh_term>
	<criteria>Center Neurologic StudyLability Scale ( CNSLS ) score 13 great Clinical diagnosis Pseudobulbar Affect ( PBA ) Documentation Neurologic disease brain injury Unstable neurologic disease Severe dementia Stroke within 3 month Penetrating TBI Contraindications Nuedexta Severe Depressive Disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>